Ondine Biomedical (FRA:VF5) Research & Development: €6.21 Mil (TTM As of Dec. 2024)


FRA:VF5 Ondine Biomedical Inc FRA:VF5
47 GF Score
Price €0.15
View Full Analysis

What is Ondine Biomedical Research & Development?

Ondine Biomedical FRA:VF5 47 Research & Development is €6.21 Mil as of Dec. 2024. GuruFocus rates FRA:VF5 with a GF Score™ of 47/100.

Research & Development is the aggregate amount of research and development expenses during the year. Ondine Biomedical's Research & Development for the six months ended in Dec. 2024 was €3.97 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €6.21 Mil.

Ondine Biomedical  (FRA:VF5) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ondine Biomedical Research & Development Related Terms

Ondine Biomedical Research & Development Historical Data

* Premium members only.

The historical data trend for Ondine Biomedical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical Research & Development Chart

Ondine Biomedical Annual Data
Trend Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.12 3.45 4.36 3.51 6.18

Ondine Biomedical Semi-Annual Data
Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.53 1.52 2.02 2.24 3.97
FRA:VF5
47GF Score
Ondine Biomedical Inc FRA:VF5
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ondine Biomedical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €6.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €6.21 Mil mean?
Ondine Biomedical (FRA:VF5) has a Research & Development of €6.21 Mil as of Dec. 2024. Research and development expense is the total cost for research and development activities. View historical data on Ondine Biomedical and its competitors.
Is Ondine Biomedical's Research & Development too high?
Ondine Biomedical's current Research & Development is €6.21 Mil. Overall, Ondine Biomedical has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Research & Development compare to VRTX and REGN?
Ondine Biomedical's Research & Development of €6.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current Research & Development is €6.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Ondine Biomedical (FRA:VF5) has a current Research & Development of €6.21 Mil. The current Research & Development is €6.21 Mil. Ondine Biomedical's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current Research & Development is €6.21 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ondine Biomedical Business Description

Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
47GF Score

Get the complete analysis for FRA:VF5

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price